EP
NTLA icon

Edgestream Partners’s Intellia Therapeutics NTLA Stock Holding History

Edgestream Partners’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-111,159
Closed -$999K – 1031
2025
Q4 		$999K Buy
+111,159
New +$1.53M 0.03% 697
2025
Q1 		– Sell
-12,974
Closed -$151K – 979
2024
Q4 		$151K Buy
+12,974
New +$202K 0.01% 828
2024
Q1 		– Sell
-21,577
Closed -$658K – 960
2023
Q4 		$658K Buy
+21,577
New +$620K 0.05% 545

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Edgestream Partners's NTLA Position: Q1 2026 in Review

Edgestream Partners sold out of Intellia Therapeutics (NTLA) in Q1 2026, closing a stake of 111,159 shares — an estimated $999K sold.

Edgestream Partners first reported a position in NTLA in Q4 2023 and held it in 3 quarters. The position peaked at $999K in Q4 2025. 304 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Edgestream Partners reported no remaining Intellia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Edgestream Partners sold 111,159 Intellia Therapeutics shares in Q1 2026, an estimated $999K.
  • Edgestream Partners first reported a position in Intellia Therapeutics in Q4 2023 and held it in 3 quarters.
  • Edgestream Partners's Intellia Therapeutics position peaked at $999K in Q4 2025.
  • 304 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Edgestream Partners's 13F filing for Q1 2026, filed 18 May 2026.